Pfizer’s Big Breakthrough for Breast Cancer
An experimental breast cancer therapy treatment from Pfizer (NYSE:PFE) has been given the Food and Drug Administration’s ‘breakthrough therapy designation.’ This recognition of the new drug could help expedite development on this drug.
This designation was awarded as a result of data that was presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. At the Symposium, the company presented findings that the women who were treated with a combination of letrozole and palbociclib achieved significant progress compared to the women who took letrozole alone.
Patients who were treated with a combination of drugs “went more than 26 months without worsening symptoms, as opposed to 7.5 months for patients only using letrozole.” The drug will go into testing for Phase III.